Drug Trial Radar · NCT07300956
Treating Young Children With Attention Deficit Hyperactivity Disorder
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
370
Planned (sponsor's estimate)
Start
Feb 16, 2026
Primary completion
Feb 2030
Study completion Jul 2030
Sponsor
- Lead sponsor
- Children's Hospital Medical Center, CincinnatiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; Children's Hospital of Philadelphia; Developmental Behavioral Pediatrics Research Network; Boston Children's Hospital, Boston, MA, USA; Children's Mercy Hospital Kansas City; Stanford University
- First posted
- Dec 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This project will evaluate the effectiveness of Methylphenidate versus Guanfacine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 3 through 5 years (inclusive), as measured by clinician rating of global improvement.
Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA)Drug
After engaging in behavioral therapy, participants randomized into this group participants will be prescribed Guanfacine. Each child's prescribing clinician determines the form and dose of guanfacine that the child receives. Guanfacine (GUA) medication brand names include: Intuniv, Tenex, guanfacine hydrochloride- extended release, guanfacine hydrochloride- immediate release
Methylphenidate (MPH)Drug
Participants randomized into this group will be prescribed Methylphenidate. Each child's prescribing clinician determines the form and dose of methylphenidate that the child receives. Methylphenidate (MPH) medication brand names include: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Relexxii, Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid), methylphenidate hydrochloride- extended release, methylphenidate hydrochloride- immediate release
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Global Impression-ImprovementTime frame: From enrollment to the end of the 16-week medication treatment.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Stanford Medicine Children's Health
Palo Alto, California · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Children's Mercy Hospital
Kansas City, Missouri · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.